Mediaboss Marketing

BURLINGTON, MA, MilliporeSigma, the US, and Canada Life Science business of Merck KGaA, Darmstadt Germany, a leading science and technology company, launched its AIDDISON drug discovery software, the first software-as-a-service platform that bridges the gap between virtual molecule design and real-world manufacturability through SynthiaTM retrosynthesis software application programing interface (API) integration.

It combines generative AI, machine learning and computer-aided drug-design to speed up drug development. Trained on more than two decades of experimentally validated datasets from pharmaceutical R&D, AIDDISON software identifies compounds from over 60 billion possibilities that have key properties of a successful drug, such as non-toxicity, solubility, and stability in the body. The platform then proposes ways to best synthesize these drugs.

With millions of people waiting for the approval of new medicines, bringing a drug to market, still takes on average, more than 10 years and costs over US$2 billion said Karen Madden, chief technology officer, Life Science business sector of Merck. Our platform enables any laboratory to count on generative AI to identify the most suitable drug-like candidates in a vast chemical space. This helps ensure the optimal chemical synthesis route for development of a target molecule in the most sustainable way possible.

Discovering drugs is a long, iterative process. Only about 10 percent of drug candidates evaluated in Phase I made it to market. To find the most suitable chemical compoundfroma universe of more than1060molecules requires significant time, resources, and expertise. Artificial Intelligence (AI) and machine learning models like AIDDISON software can extract hidden insights from huge datasets, thus increasing the success rate of delivering new therapies to patients. AI has the potential to offer more than US$70 billion in savings for the drug discovery process by 2028, and to save up to 70 percent time and costs for drug discovery in pharmaceutical companies.

Follow this link:
First Ever AI Solution to Integrate Drug Discovery and Synthesis - Lab Manager Magazine

Tags: